The list of illnesses that seem to benefit from treatment with GLP-1 agonists seems to get ever longer, and a study has ...

Reimbursement authority NICE has turned down routine NHS use of Roche's Itovebi for a specific form of breast cancer, a ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

Fragmented data does more than slow trials down. In some cases, it can limit eligible patients from participating in a trial ...

Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with mid-stage clinical data for a new shot covering 25 strains – five more than its current Prevnar 20 ...

Takeda's $300 million wager on Protagonist Therapeutics' rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off. The first phase 3 trial of the injectable hepcidin mimetic, ...

GSK is preparing to cut more than 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched ...

By the time someone reached me, they had often been on a diagnostic journey for years – misdiagnosed, undertreated, cycling ...

Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign that ran in the EU, ...

The Federal Trade Commission (FTC) and several US states have accused Martin Shkreli of violating a lifetime restraining ...

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encouraging results ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access scheme ...